N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Intensive Cancer Screening After Cryptogenic Stroke

Sponsor: Ottawa Hospital Research Institute • ClinicalTrials.gov ID: NCT05733416

Registry updated: 2026-10-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.

Interventions

  • FDG PET/CT (Diagnostic test)
    F-fluorodeoxyglucose positron emission/computed tomography
  • Usual Care (Diagnostic test)
    Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care

Eligibility criteria

Inclusion Criteria: * adults ≥18 years * presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke) * patient or delegate willing and able to provide informed consent. Exclusion Criteria: * contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes) * active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)

Conditions

Occult Cancer

Locations

  • Calgary Foothills Medical Centre — Calgary, Alberta, Canada
  • The Ottawa Hospital — Ottawa, Ontario, Canada
  • Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record